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T2N0M0 tumors those received conventionally dose fraction 
schedule, by age group, less than 65 years old or greater. 
 
Material and Methods: Between 2005 and 2008, 72 patients 
with cT1N0M0 and 47 with cT2N0M0 glottic cancer were 
treated with radical conventional radiotherapy (2Gy/fraction, 
5 days per week total dose 70Gy and 72 Gy: group 1), 87/119 
over 65 years old. Between 2009 and 2013, 34 patients with 
cT1N0M0 and 31 with cT2N0M0 glottic cancer were treated 
with radical hypofractionated radiotherapy (2.75Gy/fraction, 
5 days per week, total dose 55Gy and 57.75Gy: group 2), 
52/65 over 65 years old.Toxicity was evaluated according to 
RTOG toxicities scale. 
 
Results: The 5-year local control was in group 1 was 86% for 
T1 and 78% for T2, in group 2 was 90% for T1 and 88% for T2, 
whereas the 5- year overall survival was in group 1: 72% for 
T1 and 67.7% for T2 ; in group 2: 73.8% for T1 and 70.7% for 
T2. The treatment was well tolerated. No significant 
statistical difference was found between the two groups, or 
by age group. Only grades 1 and 2 acute skin and dysphonia 
toxicity with good voice quality were observed and no 
evidence of severe late toxicity. 
 
Conclusion: Hypofractionated radiotherapy proved beneficial 
por T1-T2 glottic carcinoma with no increase of toxicity and a 
good local control, well tolerated in older patients, over 65 
years. 
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Purpose or Objective: To evaluate stereotactic body 
radiation therapy (SBRT) for primary lung tumors in patients 
over 75 years old. 
 
Material and Methods: Between 2002 and 2015, 62 elderly 
patients with 65 lung primary tumors (T1-T2N0M0) were 
treated using SBRT at our institution. SBRT procedure 
involved: Slow-scan computed tomography (CT) simulation 
with immobilization devices, contouring the target volume in 
3 sets of CTs, superimposing the volumes in the planning 
system to represent the internal target volume and dose 
calculation using heterogeneity correction. Radiation delivery 
with multiple static planar or non-coplanar beams and arc 
therapy assured conformal dose distribution and steep fall-off 
of the radiation. The prescribed dose was 3 fractions of 15 Gy 
each (90%) over 6 to 10 days or a single 30-Gy fraction (10%). 
Dosimetric constraints were set for surrounding organs at 
risk. Repeated cone-beam CT (2 previous and 1 after 
radiation administration) were used to verify and adjust daily 
positioning. Toxicity and radiologic response were assessed in 
follow-up visits, using standardized criteria (RTOG and 
RECIST) and analyzed retrospectively. Survival rates and 
toxicities were calculated by the Kaplan-Meier method. 
 
Results: Median patient age was 81 years (75-88). All patients 
had good performance status at the moment of treatment 
(ECOG PS 0-1). Because of patient’s comorbidities or 
preferences, none were surgical candidates. The FEV1 was 
over 30 % of predicted in all cases. 7 % of all patients also 
received systemic treatment before or after SBRT. 83 % of 
the patients had 18-FDG PET-CT previous to SBRT. Histology 
included: epidermoid (48 %), adenocarcinoma (14 %), 
undifferentiated NSCLC (19 %), microcytic/neuroendocrine (4 
%) and PET positive tumors without histology (15%). Mean 
tumor volume was 28.4 cm3 (1.2-143). Transient grade 1 or 2 
acute toxicities (cutaneous erythema, esophagitis or 
respiratory symptoms) occurred in 18.4% of all cases. No 
grade > 3 acute or any chronic toxicities were identified. The 
median follow-up was 24 months (3-65). The overall and 
cancer-specific survivals were: 80 and 85 % at 1 year and 64 % 
and 70 % at 2 years. Control in the irradiated volume is 98 %, 
the only relapse occurring in a patient with neuroendocrine 
histology. 
 
Conclusion: SBRT is an excellent treatment option for lung 
tumors in elderly patients in whom other treatment options 
might be limited. Our encouraging results are in line with 
those reported in recent literature for younger patients. 
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Purpose or Objective: Participation of patients in trials and 
quality of trial data collection are important factors 
hampering successful execution of clinical trials. Our aim was 
to design a system to increase patient participation in clinical 
radiotherapy trials and to install a process that would lead to 
a higher quality of data collection during treatment and 
follow-up. 
 
Material and Methods: In 2013 we implemented a Trial 
Outpatient Clinic (TOC) for prospective screening of all 
patients referred to our radiotherapy institute, in order to 
identify potential trial candidates and to support radiation 
oncologists during the informed consent procedure and the 
work-up phase before the patients’ treatment within the 
trial. During treatment and follow-up, dedicated TOC 
consultations facilitate a rearrangement in trial data 
collection from radiation oncologists to trial (physician) 
assistants of the TOC.  
Patient inclusion in trials was measured in relation to the 
total number of radiotherapy treatments in our institute per 
year from 2005 to 2014. Quality of data collection was 
subjectively analysed based on completeness of CRF’s and 
consistency of data. In addition, a questionnaire was 
provided to a random subset of seventeen trial participants 
to evaluate their satisfaction with the TOC. Interviews with 
seven radiation oncologists were performed to evaluate their 
experience with the TOC. 
 
Results: The percentage of trial patients as compared to the 
total number of treatments declined between 2005 and 2008 
from 6.6% to 3.8%. After implementing the TOC, this number 
increased to 5.3%. In 2014 we observed an increase to 9.3% 
despite a decline in the number of trials open for inclusion in 
the last two years. CRF’s were found to be more consistent 
and complete. The participants’ questionnaire showed that 
82% was very satisfied having one contact person for trial 
related issues and 71 % thought that the existence of the TOC 
had added value. Participants did not think it bothersome 
having additional consultations and experienced an extra 
benefit by becoming more familiar with TOC personnel. 
Radiation oncologists were satisfied about the TOC as 
rearrangement of data recording was beneficial to them and 
less laborious. 
 
